Search

Items tagged with: BioTech

🐍💉 Tim Friede spent nearly 20 years gradually immunizing himself against #venom from over a dozen deadly #snakes, including #cobras and black #mambas.

Scientists used #antibodies from his blood to create an experimental #antivenom that protected #mice from 13 types of snake venom. The work could lead to a single broad-spectrum antivenom.

👉 sciencenews.org/article/antive…

#science #immunology #biology #wildlife #medicine #research #nature #wisconsin #newyork #biotech

A man let snakes bite him 202 times. His blood helped create a new antivenom

A new antivenom relies on antibodies from the blood of Tim Friede, who immunized himself against snakebites by injecting increasing doses of venom into his body.
Science News Magazine (Science News)
#nature #wildlife #science #research #medicine #biology #biotech #immunology #newyork #Venom #snakes #cobras #mambas #antibodies #antivenom #mice #wisconsin

Teresita’s Dream: Cuba’s Battle Against Alzheimer’s

When her mother was diagnosed with Alzheimer’s, Cuban scientist Teresita Rodríguez set out to find a way to help her. At the time, her colleagues at Cuba’s Center for Molecular Immunology, were dev...
Videos about Cuba from 'Belly of the Beast' (PeerTube.world)
#news #cuba #us #documentary #video #politics #medicine #healthcare #biotech #alzheimer #sanctions #bellyofthebeast #havana #oilforcuba #endtheblockadeembargo #cubasolidarity #letcubalive #endsanctionsagainstcuba #petroleoparacuba #latinamerica #caribbean #film

The media in this post is not displayed to visitors. To view it, please go to the original post.
Novel mirror-image amino acid shows promise in targeting cancer cells while preserving healthy tissue, offering a more selective approach to cancer treatment. #Oncology #BioTech
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Oragenics files 2025 10-K with major milestones: NYSE compliance restored, $16.5M capital raise, U.S. manufacturing transition, and Phase IIa trials planned for brain-targeted ONP-002. #Biotech #Healthcare
#healthcare #biotech

Vesicor Therapeutics appoints Michael Tolentino, M.D. as CEO to lead p53-based cancer therapeutic platform toward FDA submission and merger with Black Hawk Acquisition. #Biotech #Healthcare
#healthcare #biotech

LIXTE Biotechnology advances PP2A inhibition strategy with LB-100 to enhance cancer treatment effectiveness by boosting tumor sensitivity and immune response. #Oncology #Biotech
#oncology #biotech

LIXTE Biotechnology advances LB-100, a PP2A inhibitor designed to enhance chemotherapy effectiveness and boost immune response in cancer treatment. #Oncology #Biotech
#oncology #biotech

Oragenics disclosed a going concern audit opinion in its 2025 Form 10-K filing. The biotech firm continues advancing ONP-002 for brain injury treatment. #Biotech #Healthcare
#healthcare #biotech

Lixte Biotech advances precision oncology with LB-100, a first-in-class therapy enhancing cancer treatment efficacy while reducing toxicity. New partnership with Liora Technologies integrates multimodal oncology data for precision-guided care. #Oncology #Biotech
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Lantern Pharma receives FDA clearance for STAR-001 pediatric CNS cancer trial, leveraging AI-driven RADR platform to target DNA repair mechanisms. Preclinical data shows promising survival improvements. #Biotech #Oncology
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Lixte Biotech advances precision oncology with LB-100, designed to enhance cancer treatment efficacy while reducing side effects. New Liora partnership integrates multimodal data for precision-guided care. #Oncology #Biotech
#oncology #biotech

LIXTE Biotechnology doubles enrollment in LB-100 clinical trial for clear cell ovarian cancer, advancing its novel immunotherapy approach. #Oncology #Biotech
#oncology #biotech

NextGen Scientific raises $10M to advance oncology and dermatology drug development through strategic investment in Ionics Life Sciences and portfolio companies Genzada Pharmaceuticals and Hyatt Life Sciences. #Biotech #Healthcare
#healthcare #biotech

Lantern Pharma advances AI-driven oncology pipeline with Phase 2 HARMONIC trial progress and planned FDA discussions in mid-2026. Portfolio targets $15B market opportunity. #Biotech #Oncology
#oncology #biotech

LIXTE Biotechnology advances LB-100, the world's only clinical-stage PP2A inhibitor, to enhance cancer immunotherapy and chemotherapy effectiveness. #Biotech #Oncology
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
LIXTE Biotechnology expands LB-100 clinical trials, doubling enrollment in its ovarian cancer study. The lead compound sensitizes cancer cells to chemotherapy, addressing critical gaps in treatment for difficult malignancies. #Oncology #Biotech
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
LIXTE Biotechnology files 2025 10-K highlighting clinical progress on LB-100, Liora acquisition, and $11M capital raise. Advancing oncology innovation. #Biotech #Oncology
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Alpha Cognition's ZUNVEYL shows accelerating adoption in long-term care. Q4 sales hit $2.5M with bottles dispensed up 62% q/q. Strong repeat ordering signals durable demand. #Healthcare #Biotech
#healthcare #biotech

LIXTE Biotechnology's LB-100 is the world's only clinical-stage PP2A inhibitor, enhancing cancer immunotherapy and chemotherapy response while disrupting tumor repair. #Oncology #Biotech
#oncology #biotech

Soligenix's HyBryte achieves 60% treatment success vs 20% for Valchlor in cutaneous T-cell lymphoma study, with zero treatment-related adverse events. #Biotech #Oncology
#oncology #biotech

Soligenix's HyBryte shows 60% treatment success vs. 20% for Valchlor in cutaneous T-cell lymphoma study, with superior safety profile. Regulatory approval pathway advancing. #Biotech #Oncology
#oncology #biotech

Heidelberg Pharma presents preclinical data for HDP-103, an Amanitin-based ADC for metastatic prostate cancer, at AACR 2026. Results show superior efficacy and manageable safety profile. #Oncology #Biotech
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Lixte Biotech advances precision oncology with LB-100, a first-in-class therapy designed to enhance cancer treatment effectiveness. Strategic partnerships and expanded clinical trials mark significant momentum. #Oncology #Biotech
#oncology #biotech

Darwin AG presents at Invest Stuttgart and Equity Forum Frankfurt this spring, showcasing personalized healthcare innovations and 2025 results to investors. #Healthcare #Biotech
#healthcare #biotech

LIXTE Biotechnology accelerates cancer innovation with Liora Technologies acquisition, advancing LB-100 across clinical programs. #Oncology #Biotech
#oncology #biotech

Lixte Biotech advances LB-100, a first-in-class therapy to enhance cancer treatment effectiveness while reducing toxicity. New strategic partnerships and expanded clinical trials mark growing momentum in precision oncology. #Oncology #Biotech
#oncology #biotech

Oragenics doses first patient in Phase IIa trial of ONP-002 for concussion treatment, a first-in-class intranasal neurosteroid addressing major unmet medical need. #Biotech #Neurology
#biotech #neurology

LIXTE Biotechnology reports 40% disease control rate in ovarian cancer trial combining LB-100 with dostarlimab, supporting expansion of patient enrollment. #Biotech #Oncology
#oncology #biotech

Kairos Pharma honored at 2026 Pinnacle Awards for innovative cancer drug resistance solutions. Lead candidate ENV-105 targets CD105 to enhance therapy effectiveness across multiple cancer indications. #Biotech #Oncology
#oncology #biotech

Oncotelic Therapeutics reports FY 2025 net income of $249M, driven by $365.4M non-cash gain from GMP Bio joint venture valuation. Clinical-stage biotech advancing oncology pipeline. #Biotech #Oncology
#oncology #biotech

A bird flu vaccine for humans is being trialled – here’s how it works
#BirdFlu #H5N1 #Vaccine #mRNA #Health #Science #Pandemic #PublicHealth #Vaccines #Healthcare #FluVaccine #Technology #WHO #Virus #CancerResearch #Biotech #Medicine #Innovation #AvianFlu
the-14.com/a-bird-flu-vaccine-…

A bird flu vaccine for humans is being trialled – here’s how it works | The-14

UK scientists are testing the first human bird flu vaccine using mRNA technology to help prevent future pandemics and protect vulnerable groups.
The 14 (The-14 Pictures)
#technology #health #science #medicine #innovation #healthcare #virus #publichealth #vaccine #biotech #vaccines #who #cancerresearch #pandemic #birdflu #h5n1 #mrna #fluvaccine #avianflu

Oncology is shifting toward combination therapies. First-in-class PP2A inhibitor LB-100 enhances existing treatments to overcome resistance, advancing multi-drug strategies in cancer care. #Oncology #Biotech
#oncology #biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. Clinical trials underway for multiple solid tumors. #Oncology #Biotech
#oncology #biotech

Lantern Pharma schedules FDA Type C meeting for HARMONIC trial amendments evaluating LP-300 in lung cancer, with data showing 8.3-month median PFS in EGFR-mutant patients. #Oncology #Biotech
#oncology #biotech

LIXTE Biotechnology advances LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness in cancer treatment. #Oncology #Biotech
#oncology #biotech

Molecular testing is revolutionizing CNS cancer diagnosis, enabling more accurate tumor identification and personalized treatment strategies for patients. #Biotech #Oncology
#oncology #biotech

Oncotelic Therapeutics highlighted for strategic asset valuation approach, leveraging its diversified pipeline and $1B+ valued stake in GMP Bio. #Biotech #Oncology
#oncology #biotech

Tonix Pharmaceuticals presents preclinical immuno-oncology data at AACR 2026, highlighting TNX-1700 and TNX-4700 as promising cancer immunotherapy candidates. #Biotech #Oncology
#oncology #biotech

Oncotelic Therapeutics featured in BioMedWire editorial on how advancing drug pipelines and AI-driven oncology innovation are reshaping biotech valuations as measurable financial assets. #Biotech #Oncology
#oncology #biotech

The media in this post is not displayed to visitors. To view it, please go to the original post.
Oncotelic Therapeutics advances oncology pipeline through strategic partnerships and AI innovation, with joint venture contributing $249M balance sheet increase. #Biotech #Oncology
#oncology #biotech

This website uses cookies to recognize revisiting and logged in users. You accept the usage of these cookies by continue browsing this website.

⇧